Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Operating Expenses (2022 - 2025)

Historic Operating Expenses for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $33.7 million.

  • Zentalis Pharmaceuticals' Operating Expenses fell 3441.05% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.1 million, marking a year-over-year decrease of 2309.52%. This contributed to the annual value of $258.6 million for FY2024, which is 1365.23% down from last year.
  • According to the latest figures from Q3 2025, Zentalis Pharmaceuticals' Operating Expenses is $33.7 million, which was down 3441.05% from $36.1 million recorded in Q2 2025.
  • In the past 5 years, Zentalis Pharmaceuticals' Operating Expenses registered a high of $103.9 million during Q2 2023, and its lowest value of $33.7 million during Q3 2025.
  • Its 4-year average for Operating Expenses is $60.1 million, with a median of $62.7 million in 2023.
  • As far as peak fluctuations go, Zentalis Pharmaceuticals' Operating Expenses soared by 6374.78% in 2023, and later plummeted by 4465.22% in 2025.
  • Zentalis Pharmaceuticals' Operating Expenses (Quarter) stood at $51.8 million in 2022, then skyrocketed by 31.24% to $67.9 million in 2023, then increased by 12.94% to $76.7 million in 2024, then tumbled by 56.03% to $33.7 million in 2025.
  • Its Operating Expenses stands at $33.7 million for Q3 2025, versus $36.1 million for Q2 2025 and $45.6 million for Q1 2025.